Clinical Trial

A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and tolerability of HRS-7525 in participants with Advanced Prostate Cancer, and to determine the dose limiting toxicity (DLT), the maximum tolerated dose (MTD, if possible), and the recommended Phase II dose (RP2D) of HRS-7525.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-04
Trial Details
NCT Number NCT07711184
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Prostate Cancer
Enrollment 320 participants
Start Date 2026-07-30
Primary Completion 2028-06 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-03